Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Item

http://www.wikidata.org/entity/Q29619877

Q29619877

about

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Fibrates for secondary prevention of cardiovascular disease and stroke Combined therapy with statins and fibrates for people with dyslipidaemia Fibrates for primary prevention of cardiovascular disease events Combined therapy with statins and fibrates for people with dyslipidaemia Statins and fibrates for preventing melanoma Role of LXRs in control of lipogenesis Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk Standards of medical care in diabetes--2012 Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit Hypertriglyceridemia: its etiology, effects and treatment Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421 Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial Withdrawal of cerivastatin from the world market Anti-atherogenic effects of fibrates in type 2 diabetes The case for low carbohydrate diets in diabetes management Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease Use of fibrates in the metabolic syndrome: A review Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.PPARs: Protectors or Opponents of Myocardial Function?Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy Role of lipotoxicity in endothelial dysfunction Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis Treatment of dyslipidemia Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands New Era of Lipid-Lowering Drugs

P2860

Q22242896-1ABB6BF3-71E0-40A3-8F6C-96F3B0A0AE52 Q24186376-7DF22302-A502-4FFE-AF40-2F3DDDAE3BF5 Q24195172-A9DB950E-9D4F-4A2E-A1F6-08436B45226E Q24203618-09C056B0-D920-4C47-81B0-FACD8091ECA7 Q24243737-C7DEF090-77BD-4541-86FA-448450828ABE Q24245521-CEA14AB5-6A54-4E89-A59C-70757DF98B75 Q24290548-2B4D96A2-45B4-47A6-91E7-05164CC0BB3E Q24533539-0596D8C8-D353-4F22-ACFD-70173F7F1239 Q24541529-016EE6D9-B6FB-4FEC-8842-122A8FB22A3D Q24603087-44482B78-43A1-4267-97D4-B11D2E6015A1 Q24608464-E31CE733-C318-487A-AD15-63E886B559EC Q24626884-53C74084-498C-4920-BC30-D2959B2A1A40 Q24632533-5FB9A1AD-EA05-4B07-8F49-F121E3FF5E31 Q24647414-09A77F99-6FBA-48E3-BCE9-95E2B4BAF460 Q24650533-90E4AFC6-AEE2-4C85-A65D-AF7323F2750A Q24672914-D6E3FBB0-CADB-45C2-8706-85D32F77C084 Q24793111-8E6DF2F1-4DC6-4969-8547-C15A4C3078FE Q24793416-CEC2E647-9B4F-4382-9358-B946B8D17F8D Q24796775-E1A4C83C-43EE-42BE-88F5-00641A900CF5 Q24802369-0125934E-E5B7-4DF4-88B4-473C5AD6A094 Q24804259-94085902-2749-4D7D-903C-72E071DF11B0 Q24804541-932F8EE7-94A6-4A73-BF79-B1C5452E93F3 Q24805756-9C2523C1-5D31-4E4B-A541-7D3D93BCE588 Q24806105-92E93478-B4A8-49E9-A833-7FE46AF162D0 Q24806904-0E3D7946-25CA-47D5-B8DB-D0DEA0F3593A Q24806921-2FD34694-FCCB-4666-98B0-701E5995012E Q24814561-A2C5AAA2-95F2-44EE-BBB1-A60B27B48E4E Q26745946-B3952020-87D8-4279-90C2-30C0E2727031 Q26765234-CC56756A-3C2D-4DC3-B290-502466AD3064 Q26766157-87DFB32D-06C7-443A-B787-A85B62901180 Q26771753-03A219B3-2880-4CB7-9A33-767311018D97 Q26829098-F2FC517C-9980-4497-BB06-8C7C8081D3E1 Q26859582-FDC3E0F6-3B7E-4093-B6D1-72DC7FC60CDC Q27000731-910EF056-5E0A-4262-9AE3-73F9E4078201 Q27006968-85855EB7-1749-436D-91D1-59D8620791E3 Q27022291-1307BE63-D9C7-451E-8CBE-CBB9AB37B3D4 Q27026114-7D2C29D4-4B75-4713-AB88-7E359734FE86 Q27643587-5D4057A4-D00E-4A20-B972-C49F7E5036C9 Q27644330-EC843B9F-BF97-4E5C-9CE0-EBAB8F0CFBDC Q28072298-763CAA19-7793-4E24-A6A7-B655A98FE386

P2860

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Item

http://www.wikidata.org/entity/Q29619877

description

1999 nî lūn-bûn

@nan

1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu